ID: ALA2376303

Max Phase: Preclinical

Molecular Formula: C18H17F2N3O4S

Molecular Weight: 409.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC[C@]1(C)NC(=O)c2cc(S(=O)(=O)Nc3ccc(F)cc3F)ccc2NC1=O

Standard InChI:  InChI=1S/C18H17F2N3O4S/c1-3-18(2)17(25)21-14-7-5-11(9-12(14)16(24)22-18)28(26,27)23-15-6-4-10(19)8-13(15)20/h4-9,23H,3H2,1-2H3,(H,21,25)(H,22,24)/t18-/m0/s1

Standard InChI Key:  APXWBCMMYGRMJI-SFHVURJKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 409.41

Molecular Weight (Monoisotopic): 409.0908

AlogP: 2.62

#Rotatable Bonds: 4

Polar Surface Area: 104.37

Molecular Species: NEUTRAL

HBA: 4

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.50

CX Basic pKa:

CX LogP: 2.93

CX LogD: 2.90

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.72

Np Likeness Score: -1.52

References

1. Barlind JG, Buckett LK, Crosby SG, Davidsson Ö, Emtenäs H, Ertan A, Jurva U, Lemurell M, Gutierrez PM, Nilsson K, O'Mahony G, Petersson AU, Redzic A, Wågberg F, Yuan ZQ..  (2013)  Identification and design of a novel series of MGAT2 inhibitors.,  23  (9): [PMID:23541669] [10.1016/j.bmcl.2013.02.084]

2. Scott JS, Berry DJ, Brown HS, Buckett L, Clarke DS, Goldberg K, Hudson JA, Leach AG, MacFaul PA, Raubo P, Robb G.  (2013)  Achieving improved permeability by hydrogen bond donor modulation in a series of MGAT2 inhibitors,  4  (9): [10.1039/C3MD00156C]

3. Devasthale P, Cheng D..  (2018)  Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).,  61  (22): [PMID:29986142] [10.1021/acs.jmedchem.8b00864]

Source

Source(1):

• Scientific Literature